{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:06:59Z","timestamp":1789110419922,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01413-0","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:33:47Z","timestamp":1789108427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent Advances in Tumor-Infiltrating Lymphocyte Therapy for Melanoma"],"prefix":"10.1007","volume":"27","author":[{"given":"Huihua","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuxuan","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9489-0627","authenticated-orcid":false,"given":"Changchun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"4","key":"1413_CR1","doi-asserted-by":"publisher","first-page":"e70090","DOI":"10.3322\/caac.70090","volume":"76","author":"H Sung","year":"2026","unstructured":"Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026;76(4):e70090. https:\/\/doi.org\/10.3322\/caac.70090.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1413_CR2","doi-asserted-by":"publisher","first-page":"e70043","DOI":"10.3322\/caac.70043","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1):e70043. https:\/\/doi.org\/10.3322\/caac.70043.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1413_CR3","doi-asserted-by":"publisher","first-page":"912","DOI":"10.21147\/j.issn.1000-9604.2025.06.04","volume":"37","author":"W Cao","year":"2025","unstructured":"Cao W, Qin K, Liu B, Chen W. Cancer statistics in China: Epidemiology, risk factors, and prevention. Chin J Cancer Res. 2025;37(6):912\u201328. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2025.06.04.","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"1413_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41572-025-00603-8","volume":"11","author":"A Tasdogan","year":"2025","unstructured":"Tasdogan A, Sullivan RJ, Katalinic A, Lebbe C, Whitaker D, Puig S, van de Poll-Franse LV, Massi D, Schadendorf D. Cutaneous melanoma. Nat Rev Dis Primers. 2025;11(1):23. https:\/\/doi.org\/10.1038\/s41572-025-00603-8.","journal-title":"Nat Rev Dis Primers"},{"key":"1413_CR5","doi-asserted-by":"publisher","first-page":"1006665","DOI":"10.3389\/fimmu.2022.1006665","volume":"13","author":"G Georgoulias","year":"2022","unstructured":"Georgoulias G, Zaravinos A. Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. Front Immunol. 2022;13:1006665. https:\/\/doi.org\/10.3389\/fimmu.2022.1006665.","journal-title":"Front Immunol"},{"issue":"3","key":"1413_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/jdv.70111","volume":"40","author":"M Reitmajer","year":"2026","unstructured":"Reitmajer M, Flatz L. Precision medicine in cutaneous melanoma-A comprehensive review. J Eur Acad Dermatol Venereol. 2026;40(3):377\u201386. https:\/\/doi.org\/10.1111\/jdv.70111.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1413_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.trecan.2025.08.002","volume":"11","author":"B Navarro Rodrigo","year":"2025","unstructured":"Navarro Rodrigo B, Ortiz Miranda Y, Corria-Osorio J, Coukos G, Harari A. Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps. Trends Cancer. 2025;11(10):993\u20131004. https:\/\/doi.org\/10.1016\/j.trecan.2025.08.002.","journal-title":"Trends Cancer"},{"key":"1413_CR8","doi-asserted-by":"publisher","unstructured":"Allen-Tejerina AM, Giannakis P, Ho Lai Yau T, Hillyar CRT, Rallis KS. Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies. Curr Oncol Rep. 2026;28(1). https:\/\/doi.org\/10.1007\/s11912-026-01750-1.","DOI":"10.1007\/s11912-026-01750-1"},{"issue":"11","key":"1413_CR9","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/s41416-026-03350-z","volume":"134","author":"R Woodford","year":"2026","unstructured":"Woodford R, Lorigan P, Oudit D, Abdulgawad A, Thistlethwaite F, Lim KHJ. Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time? Br J Cancer. 2026;134(11):1501\u20139. https:\/\/doi.org\/10.1038\/s41416-026-03350-z.","journal-title":"Br J Cancer"},{"issue":"19","key":"1413_CR10","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-25-0880","volume":"31","author":"L Hu","year":"2025","unstructured":"Hu L, Fan C, Bross P, Das A, Cho ES, Knudson KM, Tegenge M, Gao Q, Brewer JR, Theoret MR, Fashoyin-Aje LA. FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti-PD-1-Based Immunotherapy. Clin Cancer Res. 2025;31(19):4004\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0880.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1413_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41571-024-00984-x","volume":"22","author":"M Lopez de Rodas","year":"2025","unstructured":"Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nat Rev Clin Oncol. 2025;22(3):163\u201381. https:\/\/doi.org\/10.1038\/s41571-024-00984-x.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1413_CR12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.ccell.2024.06.015","volume":"42","author":"AA Sarnaik","year":"2024","unstructured":"Sarnaik AA, Hwu P, Mule JJ, Pilon-Thomas S. Tumor-infiltrating lymphocytes: A new hope. Cancer Cell. 2024;42(8):1315\u20138. https:\/\/doi.org\/10.1016\/j.ccell.2024.06.015.","journal-title":"Cancer Cell"},{"issue":"18","key":"1413_CR13","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-25-0882","volume":"31","author":"R Alvarez-Rodriguez","year":"2025","unstructured":"Alvarez-Rodriguez R, Vuchkovska A, Wang Z, Chartier C, Hege K, Kalos M, Kelley SO. Going with the Flow: Circulating Tumor-Reactive Lymphocytes Stream into Cancer Therapy. Clin Cancer Res. 2025;31(18):3844\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0882.","journal-title":"Clin Cancer Res"},{"key":"1413_CR14","doi-asserted-by":"publisher","first-page":"101590","DOI":"10.1016\/j.lanepe.2026.101590","volume":"64","author":"V Moreno","year":"2026","unstructured":"Moreno V, Thistlethwaite F, Yarza R, Tak WS, Lim KHJ, Haanen J. Advances in cell therapy for solid tumours: European perspective and future directions. Lancet Reg Health Eur. 2026;64:101590. https:\/\/doi.org\/10.1016\/j.lanepe.2026.101590.","journal-title":"Lancet Reg Health Eur"},{"key":"1413_CR15","doi-asserted-by":"publisher","unstructured":"Betof Warner A, Hamid O, Komanduri K, Amaria R, Butler MO, Haanen J, Nikiforow S, Puzanov I, Sarnaik A, Bishop MR, Schoenfeld AJ. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J Immunother Cancer. 2024;12(2). https:\/\/doi.org\/10.1136\/jitc-2023-008735.","DOI":"10.1136\/jitc-2023-008735"},{"key":"1413_CR16","doi-asserted-by":"publisher","first-page":"1801722","DOI":"10.3389\/fimmu.2026.1801722","volume":"17","author":"JF Wu","year":"2026","unstructured":"Wu JF, Abid MA, Singh SP, Mohlere V, Abid MB. Evolving therapeutic pipeline for tumor-infiltrating lymphocytes in metastatic melanoma - a review. Front Immunol. 2026;17:1801722. https:\/\/doi.org\/10.3389\/fimmu.2026.1801722.","journal-title":"Front Immunol"},{"issue":"3","key":"1413_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41571-023-00848-w","volume":"21","author":"S Klobuch","year":"2024","unstructured":"Klobuch S, Seijkens TTP, Schumacher TN, Haanen J. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat Rev Clin Oncol. 2024;21(3):173\u201384. https:\/\/doi.org\/10.1038\/s41571-023-00848-w.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1413_CR18","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"29","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner A, Corrie PG, Hamid O. Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future. Clin Cancer Res. 2023;29(10):1835\u201354. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1922.","journal-title":"Clin Cancer Res"},{"key":"1413_CR19","doi-asserted-by":"publisher","unstructured":"Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10(12). https:\/\/doi.org\/10.1136\/jitc-2022-005755.","DOI":"10.1136\/jitc-2022-005755"},{"issue":"33","key":"1413_CR20","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1200\/JCO-25-00765","volume":"43","author":"T Medina","year":"2025","unstructured":"Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, Thomas SS, Wermke M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Larkin J, Weber J, Graf Finckenstein F, Chou J, Gastman B, Wu X, Fiaz R, Sarnaik AA, Investigators C. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. J Clin Oncol. 2025;43(33):3565\u201372. https:\/\/doi.org\/10.1200\/JCO-25-00765.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1413_CR21","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/cac2.70050","volume":"45","author":"H Kluger","year":"2025","unstructured":"Kluger H, Grigoleit GU, Thomas S, Domingo-Musibay E, Chesney JA, Sanmamed MF, Medina T, Ziemer M, Whitman E, Finckenstein FG, Gastman B, Chou J, Wu X, Sulur G, Fiaz R, Qi R, Sarnaik AA. Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Commun (Lond). 2025;45(10):1229\u201334. https:\/\/doi.org\/10.1002\/cac2.70050.","journal-title":"Cancer Commun (Lond)"},{"issue":"23","key":"1413_CR22","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, Met O, Kessels R, Geukes Foppen MH, Stoltenborg Granhoj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retel VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel F, Ellebaek E, Holmich LR, van Akkooi ACJ, van Houdt WJ, Wouters M, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen J. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022;387(23):2113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2210233.","journal-title":"N Engl J Med"},{"issue":"2suppl","key":"1413_CR23","doi-asserted-by":"publisher","first-page":"S978","DOI":"10.1016\/j.annonc.2025.08.2277","volume":"36","author":"W Tak","year":"2025","unstructured":"Tak W, Jedema I, Seijkens T, Nuijen B, Kouwen S, Nijenhuis C, Klous M, Van Den Haak E, Dirven I, Delfos MJAoO. 1649P First real-world data for TIL therapy in patients with metastatic cutaneous melanoma. Ann Oncol. 2025;36(2suppl):S978\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2277.","journal-title":"Ann Oncol"},{"issue":"16suppl","key":"1413_CR24","doi-asserted-by":"publisher","first-page":"e21508","DOI":"10.1200\/JCO.2025.43.16_suppl.e21508","volume":"43","author":"J Yang Sr","year":"2025","unstructured":"Yang Sr J, Zhang Sr C. Safety, tolerance, and preliminary efficacy of autologous tumor-infiltrating lymphocytes (TILs) LM103 injection in Chinese patients with advanced melanoma and an exploration of the factors influencing the therapeutic effect. J Clin Oncol. 2025;43(16suppl):e21508. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e21508.","journal-title":"J Clin Oncol"},{"issue":"8suppl","key":"1413_CR25","doi-asserted-by":"publisher","first-page":"LB414","DOI":"10.1158\/1538-7445.AM2026-LB414","volume":"86","author":"C Cui","year":"2026","unstructured":"Cui C, Zhou L, Kong Y, Wang X, Yang Y, Liu J, Tan Z, Chi Z, Si L, Lian BJCR. Abstract LB414: Updated clinical efficacy and translational biomarker analysis of tumor infiltrating lymphocyte therapy (LM103) in metastatic melanoma. Cancer Res. 2026;86(8suppl):LB414\u2013414. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-LB414.","journal-title":"Cancer Res"},{"issue":"16suppl","key":"1413_CR26","doi-asserted-by":"publisher","first-page":"9548","DOI":"10.1200\/JCO.2025.43.16_suppl.9548","volume":"43","author":"C Cui","year":"2025","unstructured":"Cui C, Zhou L, Kong Y, Wang X, Chi Z, Li F, Si L, Lian B, Mao L, Yang Y. Influence of tumor infiltrating lymphocytes (TIL) monotherapy on persistent clinical and immunological responses in Asian metastatic melanoma patients with specific CD8\u2009+\u2009TIL proportions: A phase I trial. J Clin Oncol. 2025;43(16suppl):9548. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9548.","journal-title":"J Clin Oncol"},{"key":"1413_CR27","doi-asserted-by":"publisher","unstructured":"Wu D, Li N, Jiang Y, Wang Y, Zhang X, Zhao YJCR. Abstract CT114: FAST TIL: A more effective cell therapy product with great potential for the treatment of solid tumors. Cancer Res. 2025;85. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-CT114. (8_ suppl_2):CT114-CT114.","DOI":"10.1158\/1538-7445.AM2025-CT114"},{"issue":"2suppl","key":"1413_CR28","doi-asserted-by":"publisher","first-page":"S979","DOI":"10.1016\/j.annonc.2025.08.2280","volume":"36","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Fang Y, Guo Z, Liu J, Deng Y, Lin J, Lan S, Wang S, Sun Z, Jiang LJAO. 1652P A phase I clinical trial of autologous tumor-infiltrating lymphocytes FAST-TIL (HS-IT101) with low-dose IL-2 for the treatment of advanced solid tumors: Subgroup analysis of melanoma. Ann Oncol. 2025;36(2suppl):S979. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2280.","journal-title":"Ann Oncol"},{"issue":"8suppl","key":"1413_CR29","doi-asserted-by":"publisher","first-page":"CT195","DOI":"10.1158\/1538-7445.AM2026-CT195","volume":"86","author":"D Wu","year":"2026","unstructured":"Wu D, Fang Y, Guo Z, Liu J, Lin J, Deng Y, Lan S, Wang S, Gao G, Wang PJCR. Abstract CT195: Fast-manufactured, low IL-2-dependent FAST-TIL for the treatment of advanced melanoma in asian patients: Median 6-month follow-up data from a phase I clinical trial. Cancer Res. 2026;86(8suppl):CT195\u2013195. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-CT195.","journal-title":"Cancer Res"},{"issue":"17suppl","key":"1413_CR30","doi-asserted-by":"publisher","first-page":"LBA9509","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA9509","volume":"44","author":"L Si","year":"2026","unstructured":"Si L, Chen Y, Zhang W, Chen J, Zou Z, Zhu D, Pu X, Li X, Zhang X, Liu J. A multicenter, randomized, controlled, open-label, phase II trial of autologous tumor-infiltrating lymphocytes (GC101 TIL) in patients with advanced melanoma. J Clin Oncol. 2026;44(17suppl):LBA9509. https:\/\/doi.org\/10.1200\/JCO.2026.44.17_suppl.LBA9509.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1413_CR31","doi-asserted-by":"publisher","first-page":"9505","DOI":"10.1200\/JCO.2024.42.16_suppl.9505","volume":"42","author":"H Gogas","year":"2024","unstructured":"Gogas H, Furness A, Thomas S, de Speville Uribe BD, Hong Y, In G, Lawrence D, Castano AG, Haefliger S, He KJESC. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor\u2013naive unresectable or metastatic melanoma: updated results from IOV-COM-202 Cohort 1A. J Clin Oncol. 2024;42(16suppl):9505\u20139505. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9505.","journal-title":"J Clin Oncol"},{"key":"1413_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fonc.2018.00044","volume":"8","author":"JE Mullinax","year":"2018","unstructured":"Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mule JJ, Pilon-Thomas S, Sarnaik AA. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol. 2018;8:44. https:\/\/doi.org\/10.3389\/fonc.2018.00044.","journal-title":"Front Oncol"},{"issue":"7suppl","key":"1413_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1200\/JCO.2017.35.7_suppl.147","volume":"35","author":"J Mullinax","year":"2017","unstructured":"Mullinax J, Weber JS, Khushalani NI, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Zager JS, Sondak VK. Final report of a pilot trial combining ipilimumab and adoptive cell therapy. J Clin Oncol. 2017;35(7suppl):147. https:\/\/doi.org\/10.1200\/JCO.2017.35.7_suppl.147.","journal-title":"J Clin Oncol"},{"key":"1413_CR34","doi-asserted-by":"publisher","first-page":"100728","DOI":"10.1016\/j.iotech.2024.100728","volume":"24","author":"D Konig","year":"2024","unstructured":"Konig D, Kasenda B, Sandholzer M, Chirindel A, Zingg A, Ritschard R, Thut H, Glatz K, Kappos EA, Schaefer D, Kettelhack C, Passweg J, Baur K, Holbro A, Buser A, Lardinois D, Jeker LT, Khanna N, Stenner F, Matter MS, Rodrigues Mantuano N, Binder M, Zippelius A, Laubli H. Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma. Immunooncol Technol. 2024;24:100728. https:\/\/doi.org\/10.1016\/j.iotech.2024.100728.","journal-title":"Immunooncol Technol"},{"key":"1413_CR35","doi-asserted-by":"publisher","first-page":"100523","DOI":"10.1016\/j.iotech.2023.100523","volume":"20","author":"D K\u00f6nig","year":"2023","unstructured":"K\u00f6nig D, Chirindel A, Sandholzer M, Zingg A, Ritschard R, Thut H, Glatz K, Kappos E, Kettelhack C, Lardinois DJI-O. Technology. 50MO Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma. Immunooncol Technol. 2023;20:100523. https:\/\/doi.org\/10.1016\/j.iotech.2023.100523.","journal-title":"Immunooncol Technol"},{"issue":"13","key":"1413_CR36","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1158\/1078-0432.CCR-24-4322","volume":"31","author":"EME Verdegaal","year":"2025","unstructured":"Verdegaal EME, Verpoorte ALC, van der Kooij MK, de Bruin L, Visser M, van der Minne CE, Weeda V, Roozen I, Jonker MA, Westra IM, Meij P, Speetjens FM, Zunder SM, Liefers GJ, Santegoets SJ, van der Burg SH, Kapiteijn EHW. Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNalpha. Clin Cancer Res. 2025;31(13):2628\u201338. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-4322.","journal-title":"Clin Cancer Res"},{"issue":"8suppl","key":"1413_CR37","doi-asserted-by":"publisher","first-page":"VIII402","DOI":"10.1093\/annonc\/mdy288.005","volume":"29","author":"T Borch","year":"2018","unstructured":"Borch T, Andersen R, Rana M, Kongsted P, Pedersen M, Nielsen M, Kjeldsen J, Kverneland A, Lorentzen C, Met \u00d6JAoO. Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients. Ann Oncol. 2018;29(8suppl):VIII402. https:\/\/doi.org\/10.1093\/annonc\/mdy288.005.","journal-title":"Ann Oncol"},{"issue":"7","key":"1413_CR38","doi-asserted-by":"publisher","first-page":"e002703","DOI":"10.1136\/jitc-2021-002703","volume":"9","author":"TH Borch","year":"2021","unstructured":"Borch TH, Harbst K, Rana AH, Andersen R, Martinenaite E, Kongsted P, Pedersen M, Nielsen M, Kjeldsen JW, Kverneland AHJJfIoC. Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. J Immunother Cancer. 2021;9(7):e002703. https:\/\/doi.org\/10.1136\/jitc-2021-002703.","journal-title":"J Immunother Cancer"},{"issue":"Suppl 2","key":"1413_CR39","doi-asserted-by":"publisher","first-page":"P49","DOI":"10.1186\/2051-1426-3-S2-P49","volume":"3","author":"A Sarnaik","year":"2015","unstructured":"Sarnaik A, Hall M, Mullinax J, Royster E, Richards A, Crago G, Zager J, Vernon S, Weber J, Pilon-Thomas, SJJfIoC. Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma. J Immunother Cancer. 2015;3(Suppl 2):P49. https:\/\/doi.org\/10.1186\/2051-1426-3-S2-P49.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1413_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/1078-0432.CCR-16-0906","volume":"23","author":"DC Deniger","year":"2017","unstructured":"Deniger DC, Kwong ML, Pasetto A, Dudley ME, Wunderlich JR, Langhan MM, Lee CR, Rosenberg SA. A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma. Clin Cancer Res. 2017;23(2):351\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0906.","journal-title":"Clin Cancer Res"},{"key":"1413_CR41","doi-asserted-by":"publisher","first-page":"100521","DOI":"10.1016\/j.iotech.2023.100521","volume":"20","author":"T Monberg","year":"2023","unstructured":"Monberg T, Pakola S, Dr\u00e9no B, Cervera-Carrascon V, Elleb\u00e6k E, Donia M, Khammari A, Kistler C, Dos Santos JM, Clubb JJI-O. Technology. 48O Safety and efficacy of combined treatment with tumor infiltrating lymphocytes (TILs) and oncolytic adenovirus TILT-123 for patients with metastatic melanoma: Results from a phase I trial. Immunooncol Technol. 2023;20:100521. https:\/\/doi.org\/10.1016\/j.iotech.2023.100521.","journal-title":"Immunooncol Technol"},{"key":"1413_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-SITC2025.0514","author":"TV Kudling","year":"2025","unstructured":"Kudling TV, Haybout L, Clubb JH, Monberg TJ, Pakola SA, Albieri B, Juteau S, Ellebaek E, Donia M, Arias V. 514 Biomarker insights and long-term outcomes of TILT-123 oncolytic adenovirus combined with tumor-infiltrating lymphocytes in refractory metastatic melanoma: results from the TUNINTIL phase 1 trial. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0514. 13(2_suppl).","journal-title":"J Immunother Cancer"},{"issue":"16suppl","key":"1413_CR43","doi-asserted-by":"publisher","first-page":"9518","DOI":"10.1200\/JCO.2025.43.16_suppl.9518","volume":"43","author":"L Haybout","year":"2025","unstructured":"Haybout L, Clubb J, Monberg T, Pakola S, Albieri B, Juteau S, Ellebaek E, Donia M, Arias V, Kudling T. Neutralizing antibodies and lymphocyte count as biomarkers in patients receiving oncolytic adenovirus TILT-123 and adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic melanoma refractory to immune checkpoint inhibitors. J Clin Oncol. 2025;43(16suppl):9518. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9518.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1413_CR44","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO.2026.44.16_suppl.2538","volume":"44","author":"V Cervera-Carrascon","year":"2026","unstructured":"Cervera-Carrascon V, Kudling T, Clubb J, Haybout L, Monberg T, Pakola S, Albieri B, Juteau S, Ellebaek E, Donia M. Extended monitoring and biomarker analysis in metastatic melanoma patients treated with TIL therapy and conditioning-replacing igrelimogene litadenorepvec virotherapy: Pre-infusion immune cell and cytokine profiles associated with survival. J Clin Oncol. 2026;44(16suppl):2538. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.2538.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1413_CR45","doi-asserted-by":"publisher","first-page":"102016","DOI":"10.1016\/j.xcrm.2025.102016","volume":"6","author":"TJ Monberg","year":"2025","unstructured":"Monberg TJ, Pakola SA, Albieri B, Ellebaek E, Donia M, Eefsen RL, Borch TH, Kudling TV, Lorentzen T, Hendel HW, Vestergaard C, Lorentzen C, Holmstroem RB, Arias V, Khammari A, Kistler C, Santos JM, Clubb JHA, Haybout L, Westergaard MCW, Met O, Quixabeira DCA, Jirovec E, Havunen R, Sorsa S, Cervera-Carrascon V, Dreno B, Hemminki A, Svane IM. Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma. Cell Rep Med. 2025;6(3):102016. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102016.","journal-title":"Cell Rep Med"},{"issue":"16suppl","key":"1413_CR46","doi-asserted-by":"publisher","first-page":"9515","DOI":"10.1200\/JCO.2024.42.16_suppl.9515","volume":"42","author":"RN Amaria","year":"2024","unstructured":"Amaria RN, McQuade JL, Davies MA, Glitza IC, Jose S, Cressman ENK, Clausell AL, Bassett RL Jr, Patel SP, Diab A. OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma. J Clin Oncol. 2024;42(16suppl):9515. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9515.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1413_CR47","doi-asserted-by":"publisher","first-page":"9519","DOI":"10.1200\/JCO.2025.43.16_suppl.9519","volume":"43","author":"RN Amaria","year":"2025","unstructured":"Amaria RN, Diab A, Tawbi HA, Glitza IC, McQuade JL, Davies MA, Ikeguchi A, Wong MK, Patel SP, Bassett RL Jr. OBX-115 engineered tumor-infiltrating lymphocytes (TIL) with regulatable membrane-bound IL15 (mbIL15): Translational data from a single-center phase 1 trial in patients (pts) with immune checkpoint inhibitor (ICI)\u2013resistant advanced melanoma. J Clin Oncol. 2025;43(16suppl):9519. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9519.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1413_CR48","doi-asserted-by":"publisher","first-page":"9517","DOI":"10.1200\/JCO.2025.43.16_suppl.9517","volume":"43","author":"JA Chesney","year":"2025","unstructured":"Chesney JA, In GK, Shoushtari AN, Moyers JT, Samhouri Y, Johnson TT, Amaria RN, Ramsingh G, Renard C, Duan R. OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)\u2013resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study. J Clin Oncol. 2025;43(16suppl):9517. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9517.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1413_CR49","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1200\/JCO.2026.44.16_suppl.9507","volume":"44","author":"A Betof","year":"2026","unstructured":"Betof A, Chesney JA, In GK, Shoushtari A, Johnson TT, Moyers JT, Samhouri Y, Long GV, Ramsingh G, Duan R. OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients with advanced melanoma that has progressed on\/after immune checkpoint inhibitors (ICI): Phase 2 results. J Clin Oncol. 2026;44(16suppl):9507. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.9507.","journal-title":"J Clin Oncol"},{"key":"1413_CR50","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2026-CT028","author":"RN Amaria","year":"2026","unstructured":"Amaria RN, Tawbi HA, Ikeguchi A, Glitza-Oliva IC, McQuade JL, Davies MA, Petrova Y, Haymaker C, Bernatchez C, Forget M-AJCR. Abstract CT028: Results of first-in-human, Phase 1 study of KSQ-001EX, an autologous tumor infiltrating lymphocyte therapy engineered to inactivate the SOCS1 gene, in patients with select advanced solid tumors. Cancer Res. 2026. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-CT028. 86(8_ suppl):CT028-CT028.","journal-title":"Cancer Res"},{"issue":"7suppl","key":"1413_CR51","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1158\/1538-7445.AM2026-3721","volume":"86","author":"D Sangurdekar","year":"2026","unstructured":"Sangurdekar D, Tobin E, Wong K, Yeri A, Ghose M, Smashnov A, Bowen K, Dodson A, Sarkis G, Carrasco MJS. Anti-tumor function and long-term persistence of KSQ-001EX, a SOCS1-edited eTIL\u00ae therapy, independent of IL-2 co-administration. Cancer Res. 2026;86(7suppl):3721. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-3721.","journal-title":"Cancer Res"},{"key":"1413_CR52","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.omto.2022.01.004","volume":"24","author":"CA Chamberlain","year":"2022","unstructured":"Chamberlain CA, Bennett EP, Kverneland AH, Svane IM, Donia M, Met O. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Mol Ther Oncolytics. 2022;24:417\u201328. https:\/\/doi.org\/10.1016\/j.omto.2022.01.004.","journal-title":"Mol Ther Oncolytics"},{"issue":"2suppl","key":"1413_CR53","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1136\/jitc-2025-SITC2025.0601","volume":"13","author":"SMH Mannering","year":"2025","unstructured":"Mannering SMH, Crowther MD, Sohlin JE, Weis-Banke SE, Met \u00d6, Svane IM. 601 Assessment of CRISPR PD-1 edited tumor-infiltrating lymphocytes in infusion products for adoptive cell therapy in metastatic melanoma. J Immunother Cancer. 2025;13(2suppl):A1\u20131534. https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0601.","journal-title":"J Immunother Cancer"},{"issue":"2suppl","key":"1413_CR54","doi-asserted-by":"publisher","first-page":"S979","DOI":"10.1016\/j.annonc.2025.08.2281","volume":"36","author":"J Sohlin","year":"2025","unstructured":"Sohlin J, Crowther M, Mannering SH, Weis-Banke S, Met \u00d6, Svane IJAO. 1653P CRISPR-PD1 modified tumor infiltrating lymphocytes for adoptive therapy for patients with metastatic melanoma. Ann Oncol. 2025;36(2suppl):S979\u201380. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2281.","journal-title":"Ann Oncol"},{"issue":"7suppl","key":"1413_CR55","doi-asserted-by":"publisher","first-page":"S952","DOI":"10.1016\/j.annonc.2022.07.1009","volume":"33","author":"J Chesney","year":"2022","unstructured":"Chesney J, Wise-Draper T, Sarnaik A, Finckenstein FG, Hari P, Jagasia M, Desai A, Suzuki A, Wu X, Warner ABJAO. 883TiP A phase I\/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC. Ann Oncol. 2022;33(7suppl):S952. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1009.","journal-title":"Ann Oncol"},{"issue":"19","key":"1413_CR56","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1158\/1078-0432.CCR-21-1171","volume":"27","author":"SJ Seitter","year":"2021","unstructured":"Seitter SJ, Sherry RM, Yang JC, Robbins PF, Shindorf ML, Copeland AR, McGowan CT, Epstein M, Shelton TE, Langhan MM, Franco Z, Danforth DN, White DE, Rosenberg SA, Goff SL. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma. Clin Cancer Res. 2021;27(19):5289\u201398. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1171.","journal-title":"Clin Cancer Res"},{"issue":"92","key":"1413_CR57","doi-asserted-by":"publisher","first-page":"eadg7995","DOI":"10.1126\/sciimmunol.adg7995","volume":"9","author":"D Barras","year":"2024","unstructured":"Barras D, Ghisoni E, Chiffelle J, Orcurto A, Dagher J, Fahr N, Benedetti F, Crespo I, Grimm AJ, Morotti M, Zimmermann S, Duran R, Imbimbo M, de Olza MO, Navarro B, Homicsko K, Bobisse S, Labes D, Tsourti Z, Andriakopoulou C, Herrera F, Petremand R, Dummer R, Berthod G, Kraemer AI, Huber F, Thevenet J, Bassani-Sternberg M, Schaefer N, Prior JO, Matter M, Aedo V, Dromain C, Corria-Osorio J, Tissot S, Kandalaft LE, Gottardo R, Pittet M, Sempoux C, Michielin O, Dafni U, Trueb L, Harari A, Laniti DD, Coukos G. Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma. Sci Immunol. 2024;9(92):eadg7995. https:\/\/doi.org\/10.1126\/sciimmunol.adg7995.","journal-title":"Sci Immunol"},{"issue":"10","key":"1413_CR58","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1016\/j.immuni.2024.08.014","volume":"57","author":"J Chiffelle","year":"2024","unstructured":"Chiffelle J, Barras D, Petremand R, Orcurto A, Bobisse S, Arnaud M, Auger A, Rodrigo BN, Ghisoni E, Sauvage C, Saugy D, Michel A, Murgues B, Fahr N, Imbimbo M, Ochoa de Olza M, Latifyan S, Crespo I, Benedetti F, Genolet R, Queiroz L, Schmidt J, Homicsko K, Zimmermann S, Michielin O, Bassani-Sternberg M, Kandalaft LE, Dafni U, Corria-Osorio J, Trueb L, Dangaj Laniti D, Harari A, Coukos G. Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma. Immunity. 2024;57(10):2466\u2013e24822412. https:\/\/doi.org\/10.1016\/j.immuni.2024.08.014.","journal-title":"Immunity"},{"issue":"14","key":"1413_CR59","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","volume":"28","author":"ST Levi","year":"2022","unstructured":"Levi ST, Copeland AR, Nah S, Crystal JS, Ivey GD, Lalani A, Jafferji M, White BS, Parikh NB, Leko V, Krishna S, Lowery F, Prickett TD, Gartner JJ, Jia L, Li YF, Sachs A, Sindiri S, Robinson W, Gasmi B, Yang JC, Goff SL, Rosenberg SA, Robbins PF. Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-PD-1 Naive and Experienced Patients with Metastatic Melanoma. Clin Cancer Res. 2022;28(14):3042\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4499.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1413_CR60","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","volume":"30","author":"U Dafni","year":"2019","unstructured":"Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol. 2019;30(12):1902\u201313. https:\/\/doi.org\/10.1093\/annonc\/mdz398.","journal-title":"Ann Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01413-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01413-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01413-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:33:48Z","timestamp":1789108428000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01413-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01413-0","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"25 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT solely to assist with language polishing and readability. All AI-assisted text was subsequently reviewed and revised by the authors, who take full responsibility for the accuracy and integrity of the final content.","order":3,"name":"Ethics","label":"Generative AI in Scientific Writing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"47"}}